Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts, Keith R. Edwards, Peter A. Calabresi, Plena Drulovic, Gavin Giovannoni, Hans-Peter Hartung, Douglas L. Arnold, Elizabeth Fisher, Richard Rudick, Sha Mi, Yi Choi, Jie Li, Yiwei Zhang, Wenting Cheng, Lei Xu, Bing Zhu*, Susan M. Green, Ih ChangAaron Deykin, Sarah Sheikh, SYNERGY study investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)845-856
Number of pages12
JournalLancet Neurology
Volume18
Issue number9
DOIs
Publication statusPublished - Sep 2019

Keywords

  • SPINAL-CORD REMYELINATION
  • CENTRAL-NERVOUS-SYSTEM
  • OLIGODENDROCYTE DIFFERENTIATION
  • LINGO-1
  • CNS
  • EXPRESSION

Cite this

Cadavid, D., Mellion, M., Hupperts, R., Edwards, K. R., Calabresi, P. A., Drulovic, P., Giovannoni, G., Hartung, H-P., Arnold, D. L., Fisher, E., Rudick, R., Mi, S., Choi, Y., Li, J., Zhang, Y., Cheng, W., Xu, L., Zhu, B., Green, S. M., ... SYNERGY study investigators (2019). Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, 18(9), 845-856. https://doi.org/10.1016/S1474-4422(19)30137-1